MedTrace Logo

How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD

NCT05359562 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-10-07

No results posted yet for this study

Summary

Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.

Conditions

  • OCD

Interventions

BEHAVIORAL

Exposure & Response Prevention (EX/RP)

Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.

Sponsors & Collaborators

  • New York State Psychiatric Institute

    collaborator OTHER

  • New York University

    collaborator OTHER

  • Research Foundation for Mental Hygiene, Inc. / Columbia University

    collaborator UNKNOWN

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Edna B Foa, PhD · University of Pennsylvania

  • Helen B Simpson, MD, PhD · New York State Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05359562 on ClinicalTrials.gov